Former Bristol-Myers Squibb Head of Pharmacometrics Dr. Amit Roy Joins PumasAI to Support Drug Development Programs and DeepPumas Application

PumasAI, a science-first organization that turns data into life-saving decisions faster, announced today that Dr. Amit Roy, former Executive Director and Head of Pharmacometrics at Bristol-Myers Squibb (BMS), has joined PumasAI as Distinguished Scientist.

In his new role, Dr. Roy will contribute to PumasAI’s growth trajectory by:

• providing model-informed drug development (MIDD) expertise to accelerate drug development programs, from pre-clinical through late-stage development and registrational submissions,
• playing a key role on the Strategic & Scientific Consulting team to support a global bench of some the world’s top pharmaceutical companies, and
• overseeing drug development projects involving DeepPumas, PumasAI’s first-to-market software for combining modeling and scientific machine learning (SciML) to unravel relationships in healthcare data.

Amit said, “I am super excited to join PumasAI on their mission to accelerate drug development, in particular through model-informed drug development. PumasAI is uniquely positioned to capitalize on the potential of MIDD by utilizing their next-generation modeling platform (Pumas), which I expect will become the future standard for quantitative clinical pharmacology. Pumas is an elegant, blazingly fast, integrated data analysis platform, and it is the only one with the capability of melding conventional pharmacometric methodology and machine learning.”

Using DeepPumas, scientists like Dr. Roy can utilize scientific modeling and machine learning together in one tool to automatically discover complex predictive factors that individualize predictions and solve challenges across drug discovery, drug manufacturing, drug development, and healthcare delivery.

“Dr. Amit Roy is the ideal scientific mind to add value to our world-class team, with his extensive experience integrating MIDD into drug development across several therapeutic areas, including cardiovascular diseases, hematology, immunology, oncology, and virology,” said Dr. Joga Gobburu, Co-Founder and CEO at PumasAI, and former U.S. Food and Drug Administration (FDA) Director, Division of Pharmacometrics. “We could think of no one better than Dr Amit Roy to lead a team of scientists who are working on business-critical MIDD projects.”

Prior to BMS, Dr. Amit Roy worked in pharmacometrics and pharmacology at Vertex Pharmaceuticals and as a professor at the University of Medicine and Dentistry of New Jersey.

To learn more about PumasAI, visit https://pumas.ai

About PumasAI

PumasAI is a global healthcare intelligence company with a vision to accelerate precision healthcare to patients. Proprietary software developed by the company includes the Pumas suite of products, an integrated modeling and simulation platform designed to multiply productivity across the drug development lifecycle, and Lyv, a clinical decision support system that leverages patient history and targeted medical data for personalized healthcare delivery. Scientists at PumasAI provide consulting with leading pharmaceutical innovators in clinical pharmacology, model-informed drug development (MIDD), pharmacometrics, front-end applications, and more. For additional information, visit www.pumas.ai